Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

Launched by NATIONAL CANCER CENTER, KOREA · Dec 4, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option for patients with a specific type of bile duct cancer called extrahepatic cholangiocarcinoma, which cannot be treated with surgery. The study aims to find out how effective and safe it is to combine two treatments: radiotherapy, which uses high-energy rays to kill cancer cells, and a technique called endoscopic intraductal radiofrequency ablation, which heats and destroys cancer tissue using radio waves.

To participate in this trial, individuals must be at least 20 years old and have a confirmed diagnosis of inoperable extrahepatic cholangiocarcinoma. Unfortunately, those with advanced cancer that has spread to other parts of the body or other specific health issues will not be eligible. If someone joins the trial, they can expect to receive the combined treatment and will be closely monitored to evaluate how well it works and any side effects. This study is still in the planning stages and is not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients 20 years of age or older, who voluntarily agree to participate in the study and sign the informed consent.
• • 2. Patients with cytopathologically diagnosed inoperable extrahepatic cholangiocarcinoma
• Exclusion Criteria:
• • 1. Patients who refuse to sign the informed consent
• • 2. Patients with metastatic cancer (stage IV) or malignant ascites
• • 3. Patients with intrahepatic cholangiocarcinoma
• • 4. Patients who are unable to undergo endoscopic procedures as determined by the investigator.
• • 5. Patients with a life expectancy of 3 months or less
• • 6. Patients with ID-RFA contraindications: pacemaker, pregnancy, uncorrected bleeding tendency (PT INR \> 1.5, platelets \< 50,000/mm3)